The IND submission achieves a final $10 million milestone payment from Roche. Effective April 25, 2024, the Company will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for the HB-700 program. The Company will publish preclinical data in an abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting.
https://finance.yahoo.com/news/hookipa-pharma-announces-fda-clearance-110100277.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.